NCT00827138 - Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

DCC-2036

150 mg BID tablets, continuous dosing of 28 day cycles

Trial Locations (10)

Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore

Emory University, Atlanta

H. Lee Moffitt Cancer Center & Research Institute, Tampa

University of Michigan Comprehensive Cancer Center, Ann Arbor

Medical College of Wisconsin, Milwaukee

University of Chicago, Chicago

The University of Kansas Cancer Center, Kansas City

MD Anderson Cancer Center, Houston

City of Hope, Duarte

Tufts Medical Center, Boston